"This is the first time that the results of a randomized clinical study to assess an antithrombotic agent in combination with thrombolysis during the acute phase of ischemic stroke have demonstrated a significant reduction in mortality; this is very likely due to fewer symptomatic intracerebral hemorrhages."
— Professor Mikael Mazighi, Coordinating Investigator of ACTIMIS Study
Key results :
AT the 8th EuropeanStroke Organisation Conference (ESOC) on May 6th, 2022, Professor Mikael Mazighi – Coordinating Investigatorfor ACTIMIS, presented the results of ACTIMIS study: "Glenzocimab, a Novel Antithrombotic, is Associated with Reduced Intracranial Hemorrhage and Mortality Rates when Combined with Standard-Of-Care Reperfusion Therapies: The ACTIMIS Study"